US 7,468,254 B2
Cytotoxicity mediation of cells evidencing surface expression of MCSP
David S. F. Young, Toronto (Canada); Susan E. Hahn, Toronto (Canada); Helen P. Findlay, Toronto (Canada); and Alison L. Ferry, Toronto (Canada)
Assigned to Arius Research Inc., Toronto, Ontario (Canada)
Filed on Sep. 24, 2004, as Appl. No. 10/949,846.
Application 10/949846 is a continuation in part of application No. 10/810744, filed on Mar. 26, 2004, granted, now 7,393,531.
Application 10/810744 is a continuation in part of application No. 10/762129, filed on Jan. 20, 2004, granted, now 7,361,342.
Application 10/762129 is a continuation in part of application No. 10/743451, filed on Dec. 19, 2003, abandoned.
Application 10/743451 is a continuation of application No. 10/348231, filed on Jan. 21, 2003, granted, now 7,009,040, filed on Mar. 07, 2006.
Prior Publication US 2005/0063967 A1, Mar. 24, 2005
Int. Cl. G01N 33/53 (2006.01); G01N 33/574 (2006.01); C07K 16/00 (2006.01)
U.S. Cl. 435—7.1  [435/7.23; 530/387.1; 530/388.1; 530/388.8] 4 Claims
 
1. A binding essay to determine a presence of cells which express the melanoma-associated chondroitin sulfate proteoglycan epitope which specifically binds to the isolated monoclonal antibody produced from the hybridome deposited with the ATCC as PTA-5643, or an antigen binding fragment thereof comprising:
providing a cell sample;
providing an isolated monoclonal antibody of antigen binding fragment thereof which binds to the same melanoma-associated chondroitin sulfate proteoglycan epitope as the monoclonal antibody produced from said hybridoma;
contacting said isolated monoclonal antibody of antigen binding fragment thereof with said cell sample; and
determining binding of said isolated monoclonal antibody or antigen binding fragment thereof with said cell sample;
whereby the presence of cells which express said melanoma-associated chondroitin sulfate proteoglycan epitope is determined.